Categorised relapse outcomes from baseline to PRISMS-15 in the lowest (MIN) and highest (MAX) quartiles by cumulative total dose of sc IFN β-1a, and by time receiving sc IFN β-1a
| Number of relapses | |||
|---|---|---|---|
| 0–5 | 6–10 | ≥11 | |
| Cumulative dose of sc IFN β-1a | |||
| MIN (n=73), n (%) | 29 (39.7) | 25 (34.2) | 19 (26.0) |
| MAX (n=72), n (%) | 41 (56.9) | 20 (27.8) | 11 (15.3) |
| Mean (SD) time on sc IFNβ-1a treatment,*years | 10.70 (4.73) | 9.45 (5.27) | 8.44 (5.23) |
*n=156 in the 0–5 relapses group; n=85 in the 6–10 relapses group; n=49 in the ≥11 relapses group.
IFN, interferon; sc, subcutaneous.